Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.

The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.

Mallucci G, Peruzzotti-Jametti L, Bernstock JD, Pluchino S.

Prog Neurobiol. 2015 Apr;127-128:1-22. doi: 10.1016/j.pneurobio.2015.02.003. Review.

2.

Drug therapy for multiple sclerosis.

Tavazzi E, Rovaris M, La Mantia L.

CMAJ. 2014 Aug 5;186(11):833-40. doi: 10.1503/cmaj.130727. Review. No abstract available.

3.

New and emerging immune-targeted drugs for the treatment of multiple sclerosis.

Palmer AM.

Br J Clin Pharmacol. 2014 Jul;78(1):33-43. doi: 10.1111/bcp.12285. Review.

4.

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.

Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, Brandes DW.

BMC Neurol. 2013 Oct 4;13:138. doi: 10.1186/1471-2377-13-138.

5.

Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

Jalilian B, Einarsson HB, Vorup-Jensen T.

Int J Mol Sci. 2012 Nov 9;13(11):14579-605. doi: 10.3390/ijms131114579. Review.

6.

Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial.

Zamboni P, Bertolotto A, Boldrini P, Cenni P, D'Alessandro R, D'Amico R, Del Sette M, Galeotti R, Galimberti S, Liberati A, Massacesi L, Papini D, Salvi F, Simi S, Stella A, Tesio L, Valsecchi MG, Filippini G; Chair of the Steering Committee..

Trials. 2012 Oct 3;13:183. doi: 10.1186/1745-6215-13-183.

7.

Multiple sclerosis: pathogenesis and treatment.

Loma I, Heyman R.

Curr Neuropharmacol. 2011 Sep;9(3):409-16. doi: 10.2174/157015911796557911.

8.

Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review.

Abu-Mugheisib M, Benecke R, Zettl UK.

Mult Scler Int. 2011;2011:219049. doi: 10.1155/2011/219049.

9.

The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis.

Iacobaeus E, Amoudruz P, Ström M, Khademi M, Brundin L, Hillert J, Kockum I, Malmström V, Olsson T, Tham E, Piehl F.

PLoS One. 2011 May 6;6(5):e19138. doi: 10.1371/journal.pone.0019138.

10.

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

Constantinescu CS, Farooqi N, O'Brien K, Gran B.

Br J Pharmacol. 2011 Oct;164(4):1079-106. doi: 10.1111/j.1476-5381.2011.01302.x. Review.

11.

Disease-modifying therapies in relapsing-remitting multiple sclerosis.

González-Andrade F, Alcaraz-Alvarez JL.

Neuropsychiatr Dis Treat. 2010 Sep 7;6:365-73.

12.

T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

O'Brien K, Gran B, Rostami A.

Immunotherapy. 2010 Jan;2(1):99-115. Review.

Items per page

Supplemental Content

Support Center